176047-66-8

Basic information

• Product Name: benzyl 2-hydroxy-5-formylbenzoate
• Synonyms: benzyl 2-hydroxy-5-formylbenzoate
• CAS NO: 176047-66-8
• Molecular Weight: 256.258
• Mol File: 176047-66-8.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: benzyl 2-hydroxy-5-formylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-hydroxy-5-formylbenzoate(176047-66-8)
• EPA Substance Registry System: benzyl 2-hydroxy-5-formylbenzoate(176047-66-8)

Safety Data

• Hazardous Substances Data: 176047-66-8(Hazardous Substances Data)

Upstream product

• 616-76-2 2-hydroxy-5-formylbenzoic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 176047-69-1 benzyl 2-(4-n-octyloxybenzoyloxy)-5-formylbenzoate 
• 239462-58-9 benzyl 2-trifluoromethylsulfonyloxy-5-formylbenzoate 
• 1401791-58-9 benzyl 5-((R)-2-benzyl-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxopropyl)-2-propoxybenzoate 
• 1401791-59-0 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzoic acid 
• 1401791-60-3 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde 
• 1401791-61-4 4-(1-adamantyl)-N-((5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxyphenyl)methyl)benzamide 
• 1361403-99-7 (R)-2-((3-(((4-(1-adamantyl)benzoyl)amino)methyl)-4-propoxyphenyl)methyl)-3-cyclohexylpropanoic acid 
• 1361404-00-3 (S)-2-((3-(((4-(1-adamantyl)benzoyl)amino)methyl)-4-propoxyphenyl)methyl)-3-cyclohexylpropanoic acid 
• 1361403-98-6 (R)-2-((3-(((4-(1-adamantyl)benzoyl)amino)methyl)-4-propoxyphenyl)methyl)-4-phenylbutanoic acid 
• 1361403-97-5 (S)-2-((3-(((4-(1-adamantyl)benzoyl)amino)methyl)-4-propoxyphenyl)methyl)-4-phenylbutanoic acid 
• 1418203-73-2 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde 
• 1401791-62-5 benzyl 5-((R)-2-benzyl-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxopropyl)-2-propoxybenzoate 
• 1401791-63-6 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzoic acid 
• 1401791-64-7 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde 

Relevant articles and documents

PYRROLOBENZODIAZEPINE DIMER PRECURSOR AND LIGAND-LINKER CONJUGATE COMPOUND THEREOF

The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility

In the continuing study directed toward the development of peroxisome proliferator-activated receptor gamma (hPPARγ) agonist, we attempted to improve the water solubility of our previously developed hPPARγ-selective agonist 3, which is insufficiently soluble for practical use, by employing two strategies: introducing substituents to reduce its molecular planarity and decreasing its hydrophobicity via replacement of the adamantyl group with a heteroaromatic ring. The first approach proved ineffective, but the second was productive. Here, we report the design and synthesis of a series of α-benzyl phenylpropanoic acid-type hPPARγ partial agonists with improved aqueous solubility. Among them, we selected (R)-7j, which activates hPPARγ to the extent of about 65% of the maximum observed with a full agonist, for further evaluation. The ligand-binding mode and the reason for the partial-agonistic activity are discussed based on X-ray-determined structure of the complex of hPPARγ ligand-binding domain (LBD) and (R)-7j with previously reported ligand-LDB structures. Preliminal apoptotic effect of (R)-7j against human scirrhous gastric cancer cell line OCUM-2MD3 is also described.